Literature DB >> 22990084

State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3.

Uwe Siebert1, Oguzhan Alagoz2, Ahmed M Bayoumi3, Beate Jahn4, Douglas K Owens5, David J Cohen6, Karen M Kuntz7.   

Abstract

State-transition modeling (STM) is an intuitive, flexible, and transparent approach of computer-based decision-analytic modeling, including both Markov model cohort simulation as well as individual-based (first-order Monte Carlo) microsimulation. Conceptualizing a decision problem in terms of a set of (health) states and transitions among these states, STM is one of the most widespread modeling techniques in clinical decision analysis, health technology assessment, and health-economic evaluation. STMs have been used in many different populations and diseases, and their applications range from personalized health care strategies to public health programs. Most frequently, state-transition models are used in the evaluation of risk factor interventions, screening, diagnostic procedures, treatment strategies, and disease management programs.

Mesh:

Year:  2012        PMID: 22990084     DOI: 10.1177/0272989X12455463

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  71 in total

1.  Myths and Misconceptions of Within-Cycle Correction: A Guide for Modelers and Decision Makers.

Authors:  Elamin H Elbasha; Jagpreet Chhatwal
Journal:  Pharmacoeconomics       Date:  2016-01       Impact factor: 4.981

2.  Viral hepatitis: Cost-effectiveness of direct-acting antivirals for chronic hepatitis C.

Authors:  Gaby Sroczynski; Uwe Siebert
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-08-20       Impact factor: 46.802

3.  Characterizing Heterogeneity Bias in Cohort-Based Models.

Authors:  Elamin H Elbasha; Jagpreet Chhatwal
Journal:  Pharmacoeconomics       Date:  2015-08       Impact factor: 4.981

4.  Economic evaluations with agent-based modelling: an introduction.

Authors:  Jagpreet Chhatwal; Tianhua He
Journal:  Pharmacoeconomics       Date:  2015-05       Impact factor: 4.981

Review 5.  An Educational Review About Using Cost Data for the Purpose of Cost-Effectiveness Analysis.

Authors:  Matthew Franklin; James Lomas; Simon Walker; Tracey Young
Journal:  Pharmacoeconomics       Date:  2019-05       Impact factor: 4.981

Review 6.  Verification of Decision-Analytic Models for Health Economic Evaluations: An Overview.

Authors:  Erik J Dasbach; Elamin H Elbasha
Journal:  Pharmacoeconomics       Date:  2017-07       Impact factor: 4.981

7.  A Decision-Analytic Model to Assess the Cost-Effectiveness of Etelcalcetide vs. Cinacalcet.

Authors:  Björn Stollenwerk; Sergio Iannazzo; Ron Akehurst; Michael Adena; Andrew Briggs; Bastian Dehmel; Patrick Parfrey; Vasily Belozeroff
Journal:  Pharmacoeconomics       Date:  2018-05       Impact factor: 4.981

8.  Modeling smoking-attributable mortality among adults with major depression in the United States.

Authors:  Jamie Tam; Gemma M J Taylor; Kara Zivin; Kenneth E Warner; Rafael Meza
Journal:  Prev Med       Date:  2020-08-27       Impact factor: 4.018

9.  Lives saved by expanding HIV treatment availability in resource-limited settings: the example of Haiti.

Authors:  April D Kimmel; Macarthur Charles; Marie-Marcelle Deschamps; Patrice Severe; Alison M Edwards; Warren D Johnson; Daniel W Fitzgerald; Jean W Pape; Bruce R Schackman
Journal:  J Acquir Immune Defic Syndr       Date:  2013-06-01       Impact factor: 3.731

10.  Comparative analysis of 5 lung cancer natural history and screening models that reproduce outcomes of the NLST and PLCO trials.

Authors:  Rafael Meza; Kevin ten Haaf; Chung Yin Kong; Ayca Erdogan; William C Black; Martin C Tammemagi; Sung Eun Choi; Jihyoun Jeon; Summer S Han; Vidit Munshi; Joost van Rosmalen; Paul Pinsky; Pamela M McMahon; Harry J de Koning; Eric J Feuer; William D Hazelton; Sylvia K Plevritis
Journal:  Cancer       Date:  2014-02-27       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.